Glaucoma, a leading cause of irreversible blindness worldwide, is primarily managed by regulating elevated intraocular pressure. However, conventional methods rely heavily on episodic clinic visits and patient-dependent drug regimens that often fail to capture the dynamic fluctuations in IOP. Dr. Zhu’s research addresses this critical gap by creating a wearable smart contact lens that not only monitors IOP continuously in vivo but also autonomously delivers medication when pathological pressure thresholds are detected, ensuring timely and personalized treatment.

The smart contact lens leverages a fully polymer-based architecture that is both biocompatible and flexible, facilitating prolonged ocular wear without compromising patient comfort. Embedded within the lens are advanced microfluidic channels and biosensors capable of sampling aqueous humor parameters with high sensitivity. The sensor data is processed in real time using machine learning algorithms engineered to discern subtle pressure variations indicative of glaucomatous progression, triggering a closed-loop response to administer therapeutics through on-demand drug release reservoirs integrated seamlessly into the lens matrix.

This multi-functional platform embodies an unprecedented synthesis of biomedical engineering, materials science, and artificial intelligence. The continuous monitoring capability offers a more comprehensive and dynamic understanding of IOP trends, transcending the limitations of standard tonometry. Furthermore, the closed-loop feedback system mitigates risks associated with over- or under-medication by regulating dosage based on precise physiological parameters, thereby optimizing therapeutic efficacy while minimizing side effects.

Preclinical evaluations have demonstrated the lens’s robustness in animal models, confirming its ability to retain optical clarity, mechanical resilience, and drug release precision under physiological conditions. Importantly, the all-polymer design circumvents issues commonly encountered with rigid electronic components, including mechanical mismatch and biofouling, thereby enhancing long-term functionality and patient adherence. These promising outcomes pave the way for translational efforts aiming to validate safety and performance in human clinical trials.

Dr. Zhu emphasizes the transformative nature of the technology, noting that “our design fundamentally shifts the paradigm from reactive to proactive ocular care by embedding intelligence directly at the disease interface.” This innovation aligns with a broader trend in biomedical research striving to develop theranostic devices—systems that unify diagnosis and therapy—in order to provide targeted, automated interventions that adapt in real time to individual patient needs.

The publication marks a seminal moment for the Terasaki Institute, underscoring its commitment to developing sophisticated, patient-centric biomedical solutions that bridge the divide between laboratory innovation and clinical utility. Stewart Han, President of the Institute, highlights that “this achievement exemplifies how interdisciplinary collaboration and translational research can generate breakthroughs that directly impact patient quality of life.”

Beyond glaucoma management, the smart contact lens platform holds potential versatility for diagnosing and treating a spectrum of ocular diseases characterized by fluctuating biomarkers, including diabetic retinopathy and uveitis. The underlying design principles could be adapted for multiplexed sensing and multi-drug release strategies, heralding a new era of personalized ophthalmic therapeutics that integrate seamlessly with daily life.

This innovation also dovetails with global efforts to harness wearable technologies for continuous health monitoring, bringing a new dimension to ambulatory diagnostics and responsive drug delivery systems. By embedding AI intelligence in a non-invasive, user-friendly device, it offers a practical solution to the increasing burden of chronic eye diseases and the need for remote, precision healthcare.

Looking ahead, the researchers aim to refine the device’s sensing specificity, enhance the durability of the drug reservoirs, and optimize the integrated AI algorithms through large-scale clinical validation. Collaboration with ophthalmologists, materials scientists, and regulatory agencies will be pivotal to ensuring the technology meets stringent safety standards and achieves wide clinical adoption.

As ocular diseases continue to impose significant healthcare challenges globally, innovations such as Dr. Zhu’s smart contact lens represent a beacon of hope. By transforming traditional disease management into a closed-loop, intelligent process, this technology promises to improve therapeutic outcomes, reduce healthcare costs, and most importantly, preserve vision and enhance the quality of life for millions of patients worldwide.

The Terasaki Institute’s breakthrough underscores the power of convergence research in crafting next-generation biomedical devices that are not merely passive tools but active participants in patient health management. It signals a paradigm shift in ophthalmology and wearable health technologies, marrying the precision of engineering with the complexities of human physiology in a compact, accessible form factor.

As this research transitions toward clinical translation, it is poised to inspire further innovations at the intersection of smart materials, biosensing, and AI-driven healthcare, guiding the future of personalized medicine towards a new frontier where treatment pathways are adaptive, automated, and intimately tuned to the nuances of individual patient behavior and disease trajectories.

Subject of Research: Not applicable

Article Title: Real-time intraocular pressure monitoring and responsive drug release in preclinical models by an all-polymer smart contact lens

News Publication Date: 8-Apr-2026

Web References: DOI: 10.1126/scitranslmed.ads9541

Image Credits: Terasaki Institute

Keywords

Medical technology; Biosensors; Ophthalmology; Wearable devices; Biomedical engineering; Drug delivery

End-stage liver disease persists as a leading cause of mortality worldwide, with transplantation representing the sole curative treatment for many patients. Yet, the stark scarcity of human donor organs creates a formidable bottleneck, leaving thousands languishing on transplant waitlists without hope of timely intervention. In this context, xenotransplantation—the transplantation of pig organs into humans—emerges as a promising but complex frontier fraught with intricate immunological hurdles that have so far stymied its clinical adoption.

Despite dramatic advances in the field of genetic engineering, enabling the modification of porcine organs to better mimic human immunological profiles, the phenomenon of xenoimmune rejection remains an obstinate barrier. Dr. Jucaud underscores the urgency of transcending current limitations by emphasizing the need for sophisticated in vitro platforms that emulate the nuanced interactions between human immune components and pig organ tissues. This, he asserts, will enable predictive, controllable strategies to mitigate adverse immune responses effectively.

The crux of the NIH-funded project lies in engineering a vascularized liver-on-a-chip device that faithfully replicates the complex architecture and function of a pig liver, including its perfusable vasculature. Unlike traditional static tissue culture or animal models, this microfluidic platform integrates living porcine liver cells with their native vascular network, engineered within a micro-scale environment amenable to real-time observation and manipulation.

Crucially, this model permits the introduction of human immune effectors—both humoral elements such as antibodies and cellular components including T cells and macrophages—to monitor their dynamic interactions with porcine tissue. By capturing antibody-mediated rejection mechanisms alongside cell-mediated immune responses within a controlled, human-relevant context, researchers can interrogate the molecular and cellular crosstalk responsible for graft injury, immune activation, and eventual rejection.

This innovative system offers the ability to unravel integral pathways underlying xenograft acceptance or failure, generating data that may direct the rational design of genetically engineered pigs with enhanced immunological compatibility. Moreover, the platform’s scalability and controllability represent a transformative alternative to in vivo animal studies, aligning with the scientific community’s shift towards ethical, reproducible, and human-relevant experimental paradigms.

Beyond its empirical contributions, the project resonates deeply with the legacy of Dr. Paul I. Terasaki, a titan of transplant immunology whose trailblazing work established foundational principles for organ matching and rejection prediction. The Terasaki Institute continues to embody his vision by harmonizing cutting-edge engineering and immunological insights into tangible innovations aimed at patient-centered solutions.

By converging expertise spanning bioengineering, clinical transplantation, and immunology, the Terasaki team envisions that the porcine liver-on-a-chip will serve as an essential bridge driving xenotransplantation from experimental curiosity to approved medical practice. The close monitoring capabilities and fine-tuned immune system modeling will accelerate preclinical evaluation of novel immunomodulatory regimens and organ modifications, thereby de-risking future clinical trials.

In a broader context, the success of this technology signals a new epoch in organ transplantation. By supplanting animal testing with sophisticated micro-engineered models, it not only promises reduced ethical concerns but also enhanced translational relevance, enabling faster iteration cycles in research and development. This shift embodies emerging regulatory trends that prioritize predictive in vitro platforms in biomedical innovation.

Immunologically, the platform’s capacity to recreate vascularized environments and flow conditions is critical because vascular integrity underpins graft survival and immune accessibility. The microfluidic system mimics physiological shear stresses and nutrient exchanges, providing environments where immune responses can be studied as they occur in vivo, a feat unachievable with conventional static cultures.

The intersection of microfluidics, tissue engineering, and immunology exemplified by this work is emblematic of the next wave of biomedical engineering aimed at solving previously intractable problems. This research exemplifies how organ-on-a-chip technologies can elucidate complex pathophysiological processes, catalyzing innovations that extend beyond transplantation to other fields such as infectious diseases and cancer.

As the project unfolds, it promises not only to generate critical insights into the mechanisms driving xenoimmune rejection but also to foster a new paradigm where biomedical innovation is deployed with speed, precision, and relevance to human health. These advances echo the Terasaki Institute’s mission to translate science into solutions that tangibly improve patient outcomes.

By bridging the interspecies immunological divide, Dr. Jucaud’s vascularized porcine liver-on-a-chip platform may ultimately unlock the full potential of xenotransplantation, offering hope to patients facing liver failure and addressing the growing disparity between organ demand and supply that has long plagued transplantation medicine.

Subject of Research: Development of a vascularized porcine liver-on-a-chip platform to study immune rejection mechanisms in pig-to-human liver xenotransplantation.

Article Title: Engineering the Future of Xenotransplantation: A Vascularized Porcine Liver-on-a-Chip as a Window into Human Immune Rejection.

News Publication Date: February 23, 2026.

Image Credits: Terasaki Institute for Biomedical Innovation.

Keywords

Transplantation, Xenografts, Immunology, Bioengineering, Liver, Organ-on-a-chip, Xenotransplantation, Immune rejection, Microfluidics, Tissue engineering, Vascularization, Biomedical innovation